OBJECTIVE—To evaluate urinary 8-hydroxydeoxyguanosine (8-OHdG) as a marker for the progression of diabetic macroangiopathic complications.

RESEARCH DESIGN AND METHODS—The content of urinary 8-OHdG, common carotid intima-media thickness (IMT), the coronary heart disease (CHD) risk score, the severity of diabetic retinopathy, and urinary albumin excretion were examined in 96 patients with type 2 diabetes, including 32 patients who had been nominated for the Kumamoto Study [Shichiri M, et al. Diabetes Care 23 (Suppl 2):B21–B29, 2000]. In addition, the patients from the Kumamoto Study were further evaluated regarding the effect of intensive insulin therapy on urinary 8-OHdG excretion.

RESULTS—The urinary 8-OHdG:creatinine ratio (U8-OHdG) was 2.5-fold higher in patients with increased HbA1c than in those with normal HbA1c (P < 0.05). In addition, U8-OHdG was 2.3-fold higher in patients with increased IMT (P < 0.005). A similar result was observed between U8-OHdG and CHD risk score (P < 0.01). U8-OHdG was significantly higher in patients with simple retinopathy (P < 0.05) and those with advanced retinopathy (P < 0.01) than in patients without retinopathy. Similarly, U8-OHdG was significantly higher in patients with albuminuria (P < 0.01). Furthermore, in the Kumamoto Study, U8-OHdG was significantly lower in the multiple insulin injection therapy group compared with the conventional insulin injection therapy group (P < 0.01).

CONCLUSIONS—Hyperglycemia independently increases 8-OHdG in patients with type 2 diabetes. 8-OHdG is a useful biomarker of not only microvascular but also macrovascular complications in patients with type 2 diabetes.

Vascular complications are the leading cause of morbidity and mortality in patients with diabetes. In adult patients with diabetes, the risk of cardiovascular disease is three- to fivefold greater than in nondiabetic subjects despite controlling for other known risk factors for cardiovascular disease (1). In addition, diabetic microangiopathy still represents one of the main causes of blindness (2), terminal renal failure (3), and amputation (4).

The outcomes of the Diabetes Control and Complication Trial (5), the Kumamoto Study (68), and the U.K. Prospective Diabetes Study (9) seem to have effectively resolved the long debate over whether chronic hyperglycemia is an important cause of diabetic vascular complications. Furthermore, the Diabetes Insulin-Glucose in Acute Myocardial Infarction Study showed that intensive insulin treatment was associated with a lower mortality rate than conventional insulin treatment in subjects with acute myocardial infarction (10). It was also reported that early atherosclerosis could be retarded by improved glycemic control in patients with type 1 diabetes (11). Therefore, hyperglycemia represents a major contributing factor to not only microvascular complications in diabetes but also macrovascular complications. Next to this, the longest-running controversy yet to be resolved concerns the identification of the mechanisms through which hyperglycemia acts as a crucial risk factor for these vascular complications.

Production of reactive oxygen species (ROS) and lipid peroxidation are increased in diabetic patients, especially in those with poor glycemic control (12). Oxidative stress may be crucial for development of diabetic vascular complications. Recently, we have shown that normalizing levels of mitochondrial ROS (MROS) prevents the three major pathways known as the causes of hyperglycemic damage: glucose-induced activation of protein kinase C, increased formation of glucose-derived advanced glycation end products, and increased glucose flux through the aldose reductase pathway (13). Because intracellular ROS can cause strand breaks in DNA and base modifications, including the oxidation of guanine residues to 8-hydroxydeoxyguanosine (8-OHdG), 8-OHdG might serve as a sensitive biomarker of intracellular oxidative stress in vivo.

In this study, to investigate the possible contribution of oxidative DNA damage to the pathogenesis of diabetic micro- and macroangiopathic complications, we measured the content of urinary 8-OHdG and mean intima-media thickness (IMT) of carotid arteries and calculated the coronary heart disease (CHD) risk score in 96 patients with type 2 diabetes.

Patients

The study group consisted of 96 outpatients with type 2 diabetes at the Hospital of Kumamoto University School of Medicine, including 32 patients who had been nominated for the Kumamoto Study during 1987–1998 (68). The Kumamoto Study was a randomized clinical trial designed to compare intensive insulin therapy using multiple insulin injections with conventional insulin injection therapy (CIT) to evaluate the effects of glycemic control on the development and progression of microvascular complications in Japanese patients with type 2 diabetes. After the end of Kumamoto Study, the salutary effect of intensive therapy on microvascular complications was explained to all patients included in the study and multiple insulin injection therapy (MIT) was recommended to the patients who had been treated with CIT. However, some patients still continued CIT for personal reasons. Therefore, in this study, 32 patients who had been nominated for the Kumamoto Study were still being treated with MIT or CIT (18 and 14 patients, respectively) after the end of the study. All of patients fulfilled the World Health Organization (WHO) diagnostic criteria for type 2 diabetes (14). Patients with disseminated cancer or a reduced life expectancy were excluded from the study group. Informed consent was obtained from each patient. In each patient, HbA1c was measured every month. The mean value for HbA1c was calculated to evaluate glycemic control during the previous year. The characteristics of the patients are shown in Table 1.

Measurement of 8-OHdG, creatinine, and albumin in urea

A morning urine sample from each patient was collected and stored frozen under N2 gas at −70°C. Urine samples were used within 1 month for the determination of 8-OHdG using a competitive ELISA kit (8-OHdG Check; Japan Institute for the Control of Aging, Shizuoka, Japan) according to the manufacturer’s instructions. The contents of creatinine and albumin in the same sample were measured using the Creatinine-Test (Wako, Osaka, Japan) and the Albuwell (Exocell), respectively.

Measurement of IMT of common carotid artery

The left and right common carotid arteries were examined in the anterior-oblique, lateral, and posterior-oblique longitudinal projections with an echotomographic system (LOGIQ 500; GE Yokogawa Medical System, Tokyo, Japan), as reported by Kawamori et al. (15).

CHD risk score

A venous blood sample was collected after an overnight fast. Plasma total and HDL cholesterol were measured with commercial enzymatic kit (Kyowa Medex, Tokyo, Japan). CHD risk score was assigned to each risk indicator, including age, total and HDL cholesterol, systolic and diastolic blood pressure, cigarette smoking, and diabetes, as described (16).

Classification of retinopathy

All of the patients underwent direct ophthalmoscopy and photography with pupils dilated. The eyes were graded as no retinopathy, simple retinopathy, or either preproliferative or proliferative retinopathy using the Davis classification (17).

Statistical analysis

Data were expressed as means ± SD. Differences between two groups were compared using the Mann-Whitney U test. Multiple comparisons were performed using the Kruskal-Wallis test followed by Scheffe’s test. Correlations between variables were tested using the Spearman rank-correlation analysis. P < 0.05 was considered statistically significant.

As shown in Fig. 1A, the urinary 8-OHdG:creatinine ratio (U8-OHdG) was 2.5-fold higher in patients with increased HbA1c than in those with normal HbA1c (63.6 ± 59.7 and 26.6 ± 13.7 μg/g creatinine in HbA1c >5.8 and <5.8%, respectively; P < 0.05). Multivariate analysis was performed between increased U8-OHdG and other cardiovascular disease risk factors, including sex, age, BMI, duration of diabetes, mean HbA1c, smoking, systolic blood pressure, and total and HDL cholesterol. Age, mean HbA1c, and smoking are independently associated with increased U8-OHdG (Table 2).

As shown in Fig. 1B, the patients were divided into two groups according to their value of mean IMT (high and normal IMT groups). High IMT and normal IMT were defined as mean IMT >1.1 and <1.1 mm, respectively (15). U8-OHdG was 2.3-fold higher in the high IMT group than in the normal IMT group (71.8 ± 63.0 vs. 30.7 ± 25.1 μg/g creatinine, respectively; P < 0.005). Similarly, a significant positive correlation existed between U8-OHdG and CHD risk score (r = 0.27, P < 0.01; Fig. 1C). Multivariate analysis between increased IMT and the cardiovascular disease risk factors sex, age, BMI, duration of diabetes, mean HbA1c, smoking, systolic blood pressure, total and HDL cholesterol, and U8-OHdG demonstrated that age, U8-OHdG, and decreased HDL cholesterol are independently associated with increased IMT (Table 2).

The relationship between the severity of diabetic retinopathy and U8-OHdG was evaluated, as shown in Fig. 1D. The patients were divided into three groups according to severity of retinopathy: no retinopathy, simple retinopathy, or either preproliferative or proliferative retinopathy. U8-OHdG was significantly higher in patients with simple retinopathy (77.2 ± 74.0 μg/g creatinine, P < 0.05) and those with either preproliferative or proliferative retinopathy (68.9 ± 51.9 μg/g creatinine, P < 0.01) than in patients without retinopathy (25.8 ± 13.5 μg/g creatinine). However, there was no significant difference between patients with simple retinopathy and those with either preproliferative or proliferative retinopathy.

The relationship between severity of diabetic nephropathy and U8-OHdG was evaluated, as shown in Fig. 1E. Albuminuria was defined as U8-OHdG >30 μg/mg creatinine (18). U8-OHdG was 1.9-fold higher in the patients with albuminuria than in those without nephropathy (82.6 ± 64.8 vs. 43.5 ± 45.7 μg/g creatinine, respectively; P < 0.01; Fig. 1E).

A total of 32 patients in this study had been nominated for the Kumamoto Study during 1987–1998 (68) and were still being treated with MIT or CIT. In patients who received MIT, the blood glucose control was better than in those who received CIT over a 10-year period (8). Mean HbA1c level during 10 years (1987–1998) was 7.2 ± 1.0 and 9.4 ± 1.3% in the MIT and CIT groups, respectively. Mean HbA1c in the previous year was 7.5 ± 1.2 and 8.8 ± 1.7% in MIT and CIT group, respectively. As shown in Fig. 2A, U8-OHdG was significantly lower in the MIT group compared with the CIT group (29.8 ± 18.5 vs. 95.5 ± 86.0 μg/g creatinine, respectively; P < 0.01). In addition, mean IMT was significantly less in the MIT group compared with the CIT group (0.99 ± 0.23 vs. 1.64 ± 0.70 mm, respectively; P < 0.001; Fig. 2B).

The present study shows the positive correlation between U8-OHdG and either HbA1c, mean IMT, or CHD risk score in type 2 diabetic patients. In addition, we showed that U8-OHdG increased in patients with albuminuria and in those with retinopathy. These data suggest that U8-OHdG is a useful marker of early micro- and macrovascular complications in type 2 diabetic patients and that increased oxidative stress could play an important role in the progression of diabetic complications.

8-OHdG is a product of oxidative DNA damage following specific enzymatic cleavage after 8-hydroxylation of the guanine base. 8-OHdG increases with aging (19), during carcinogenesis (20), during radiotherapy (21), in smokers (22), and in patients with diabetes (23). Recently, the content of 8-OHdG in the urine and that of the isolated mononuclear cells from type 2 diabetic patients with either retinopathy or nephropathy were reported to be much higher than those in patients without these complications (24). A similar trend was observed in our results of the association between U8-OHdG and either diabetic retinopathy or nephropathy, although we could not find significant difference of U8-OHdG between the patients with simple retinopathy and those with advanced retinopathy. Therefore, it is suggested that U8-OHdG could be a sensitive biomarker especially for the patients with early stages of diabetic complications.

The detection of early changes of atherosclerosis by noninvasive and quantitative methods is mandatory. Several cross-sectional community-based studies and follow-up studies have shown a strong and graded association between increased IMT and increased incidences of CHD and stroke (25). In addition, Kawamori et al. (15) reported that diabetic patients showed increased mean IMT compared with nondiabetic subjects and suggested that mean IMT was also useful in evaluating clinical manifestations of atherosclerosis in diabetic individuals. The CHD risk score reported by Framingham Heart Study was assigned to risk indicators, including age, HDL and total cholesterol, systolic and diastolic blood pressure, cigarette smoking, and diabetes, allowing estimation of an individual’s 10-year risks of CHD in a population free from CHD at baseline (16). This point score has been used to classify each patient’s vascular risk (16). Increased mean IMT of the carotid arteries and CHD risk score are considered to be useful markers of atherosclerosis, even in diabetic patients. In the present study, we show that U8-OHdG is elevated in patients with either increased IMT or higher CHD risk score. In addition, multivariate analysis shows that U8-OHdG, age, and decreased HDL cholesterol are independent risk factors for increased IMT. In accordance with our results, Taniwaki et al. (26) reported that age and decreased HDL cholesterol were the independent risk factors for increased IMT in type 2 diabetic patients. However, to the best of our knowledge, there is no other report to show the association between IMT and U8-OHdG.

Increased oxidative stress has been considered to be one of the common pathogenic factors of diabetic complications. However, the mechanisms by which hyperglycemia increases the productions of ROS are not fully understood. Recently, we have shown a hypothesis that MROS is a main cause of the progression of diabetic complications (13). However, it is still unclear whether this ROS from mitochondria could progress diabetic complications in vivo. In the present study, we show that mean HbA1c is independently associated with U8-OHdG. In addition, U8-OHdG increases in accordance with the severity of diabetic complications in patients with type 2 diabetes. It has been reported that the steady-state burden of oxidative adducts, such as 8-OHdG, was 16-fold higher in mtDNA than in nuclear DNA in rat liver (27). Furthermore, it has been reported that a 4,977-bp deletion in mitochondrial DNA and 8-OHdG content in muscle DNA increased in proportion to the severity of diabetic retinopathy or nephropathy in type 2 diabetic patients (24). Because 8-OHdG is a product of oxidative DNA damage and most 8-OHdG is generated in mitochondria, these findings suggest that hyperglycemia induces MROS, which contributes, at least in part, to the pathogenesis of diabetic complications in vivo.

The Kumamoto Study was a randomized clinical trial designed to compare MIT and CIT to evaluate the effects of glycemic control on the development and progression of microvascular complications in Japanese patients with type 2 diabetes (68). In the Kumamoto Study, we reported that intensive glycemic control can delay the onset and progression of early stages of diabetic microvascular complications. However, there is still considerable controversy with respect to the precise mechanism by which hyperglycemia contributes to the development of macrovascular complications. In the present study, we found that U8-OHdG was significantly lower in the MIT group compared with the CIT group in some patients from the Kumamoto Study after more than 10 years of insulin therapy. Furthermore, we showed that mean IMT was significantly less in the MIT group than in the CIT group. Although we never knew the content of U8-OHdG or the value of mean IMT in those patients at commencement of the Kumamoto Study, these findings suggest that intensive glycemic control could normalize or reduce oxidative stress and consequently delay the onset and progression of early stages of diabetic micro- and macrovascular complications. Further prospective follow-up study will be required to determine whether intensive glycemic control can actually decrease oxidative DNA damage in diabetic patients.

In conclusion, hyperglycemia independently increases 8-OHdG in type 2 diabetic patients and 8-OHdG is a useful biomarker of not only microvascular but also macrovascular complications in patients with type 2 diabetes. Blocking intracellular ROS formation, through mitochondrial electron transport chains, could offer an additional strategy for the potential prevention of diabetic micro- and macrovascular complications, which deserves further exploration.

Figure 1—

The relationship between U8-OHdG and HbA1c or severity of diabetic complications in patients with type 2 diabetes. Values are means ± SD. The relationship between U8-OHdG and HbA1c (A), mean IMT of the common carotid artery (B), CHD risk score (C), and severity of diabetic retinopathy (D), as well as U8-OHdG (E). A: The patients are divided into two groups according to their level of HbA1c (>5.8 or <5.8%). B: The patients are divided into two groups according to their value of mean IMT (>1.1 or <1.1 mm). C: U8-OHdG is plotted against CHD risk score. D: The patients are divided into three groups according to severity of retinopathy (no retinopathy, simple retinopathy, or either preproliferative or proliferative retinopathy). E: The patients are divided into two groups according to the value of the U8-OHdG (>30 or <30 μg/mg creatinine).

Figure 1—

The relationship between U8-OHdG and HbA1c or severity of diabetic complications in patients with type 2 diabetes. Values are means ± SD. The relationship between U8-OHdG and HbA1c (A), mean IMT of the common carotid artery (B), CHD risk score (C), and severity of diabetic retinopathy (D), as well as U8-OHdG (E). A: The patients are divided into two groups according to their level of HbA1c (>5.8 or <5.8%). B: The patients are divided into two groups according to their value of mean IMT (>1.1 or <1.1 mm). C: U8-OHdG is plotted against CHD risk score. D: The patients are divided into three groups according to severity of retinopathy (no retinopathy, simple retinopathy, or either preproliferative or proliferative retinopathy). E: The patients are divided into two groups according to the value of the U8-OHdG (>30 or <30 μg/mg creatinine).

Close modal
Figure 2—

The effect of intensive insulin therapy on the U8-OHdG and IMT in type 2 diabetic patients from the Kumamoto Study. Values are means ± SD. The values of the U8-OHdG and IMT in patients treated by MIT or CIT in the Kumamoto Study are shown in A and B, respectively.

Figure 2—

The effect of intensive insulin therapy on the U8-OHdG and IMT in type 2 diabetic patients from the Kumamoto Study. Values are means ± SD. The values of the U8-OHdG and IMT in patients treated by MIT or CIT in the Kumamoto Study are shown in A and B, respectively.

Close modal
Table 1—

Clinical characteristics of type 2 diabetic patients

Treatment
DietOral hypoglycemic agentsCITMIT
Sex (men/women) 5/7 20/13 11/8 19/13 
Age (years) 61.2 ± 9.8 64.2 ± 11.3 65.3 ± 9.4 60.1 ± 9.3 
BMI (kg/m222.1 ± 7.4 24.3 ± 7.5 22.5 ± 10.0 23.5 ± 6.8 
Duration of diabetes (years) 10.7 ± 7.8 14.0 ± 9.0 23.2 ± 9.4 18.1 ± 12.6 
Mean HbA1c (%) 6.5 ± 1.2 7.8 ± 1.3 8.2 ± 1.5 7.4 ± 1.1* 
Smoking (yes/no) 6/6 20/13 9/10 12/20 
Systolic blood pressure (mmHg) 127.1 ± 15.3 133.2 ± 15.4 139.6 ± 13.9 124.8 ± 15.7* 
Total cholesterol (mg/dl) 208.3 ± 33.7 193.5 ± 45.7 212.1 ± 45.0 192.4 ± 38.9 
HDL cholesterol (mg/dl) 61.8 ± 20.8 51.6 ± 14.7 56.3 ± 13.8 63.4 ± 20.8 
Mean IMT (mm) 1.33 ± 0.62 1.57 ± 0.54 1.64 ± 0.67 1.26 ± 0.61* 
CHD score 15.9 ± 13.8 17.4 ± 8.6 20.8 ± 11.5 13.0 ± 8.7* 
U8-OHdG (μg/g creatinine) 37.9 ± 29.6 70.3 ± 58.8 91.2 ± 76.1 37.2 ± 35.0* 
Treatment
DietOral hypoglycemic agentsCITMIT
Sex (men/women) 5/7 20/13 11/8 19/13 
Age (years) 61.2 ± 9.8 64.2 ± 11.3 65.3 ± 9.4 60.1 ± 9.3 
BMI (kg/m222.1 ± 7.4 24.3 ± 7.5 22.5 ± 10.0 23.5 ± 6.8 
Duration of diabetes (years) 10.7 ± 7.8 14.0 ± 9.0 23.2 ± 9.4 18.1 ± 12.6 
Mean HbA1c (%) 6.5 ± 1.2 7.8 ± 1.3 8.2 ± 1.5 7.4 ± 1.1* 
Smoking (yes/no) 6/6 20/13 9/10 12/20 
Systolic blood pressure (mmHg) 127.1 ± 15.3 133.2 ± 15.4 139.6 ± 13.9 124.8 ± 15.7* 
Total cholesterol (mg/dl) 208.3 ± 33.7 193.5 ± 45.7 212.1 ± 45.0 192.4 ± 38.9 
HDL cholesterol (mg/dl) 61.8 ± 20.8 51.6 ± 14.7 56.3 ± 13.8 63.4 ± 20.8 
Mean IMT (mm) 1.33 ± 0.62 1.57 ± 0.54 1.64 ± 0.67 1.26 ± 0.61* 
CHD score 15.9 ± 13.8 17.4 ± 8.6 20.8 ± 11.5 13.0 ± 8.7* 
U8-OHdG (μg/g creatinine) 37.9 ± 29.6 70.3 ± 58.8 91.2 ± 76.1 37.2 ± 35.0* 

Data are means ± SD. Mean values for HbA1c were calculated during the previous year.

*

P < 0.05 vs. CIT.

Table 2—

Possible contributing factors of the increased U8-OHdG or mean IMT in type 2 diabetic patients

Risk factorsU8-OHdG
Mean IMT
Standard partial regression coefficientF (Probability)Standard partial regression coefficientF (Probability)
Sex (men = 1, women = 0) −0.024 0.055 (0.8) −0.194 1.195 (0.3) 
Age (years) 0.208 4.108 (0.05) 0.281 6.970 (0.01) 
BMI (kg/m2−0.143 2.133 (0.1) −0.049 0.231 (0.6) 
Duration of diabetes (years) 0.070 0.531 (0.5) 0.105 1.096 (0.1) 
Mean HbA1c (%) 0.347 11.821 (0.001) −0.116 1.299 (0.3) 
Smoking (yes = 1, no = 0) 0.209 4.458 (0.04) −0.023 0.049 (0.8) 
Systolic blood pressure (mmHg) 0.124 1.601 (0.2) 0.049 0.231 (0.6) 
Total cholesterol (mg/dl) 0.065 0.488 (0.5) −0.046 0.238 (0.6) 
HDL cholesterol (mg/dl) −0.114 1.318 (0.3) −0.205 3.702 (0.05) 
U8-OHdG (μg/g creatinine) — — 0.212 4.425 (0.04) 
Risk factorsU8-OHdG
Mean IMT
Standard partial regression coefficientF (Probability)Standard partial regression coefficientF (Probability)
Sex (men = 1, women = 0) −0.024 0.055 (0.8) −0.194 1.195 (0.3) 
Age (years) 0.208 4.108 (0.05) 0.281 6.970 (0.01) 
BMI (kg/m2−0.143 2.133 (0.1) −0.049 0.231 (0.6) 
Duration of diabetes (years) 0.070 0.531 (0.5) 0.105 1.096 (0.1) 
Mean HbA1c (%) 0.347 11.821 (0.001) −0.116 1.299 (0.3) 
Smoking (yes = 1, no = 0) 0.209 4.458 (0.04) −0.023 0.049 (0.8) 
Systolic blood pressure (mmHg) 0.124 1.601 (0.2) 0.049 0.231 (0.6) 
Total cholesterol (mg/dl) 0.065 0.488 (0.5) −0.046 0.238 (0.6) 
HDL cholesterol (mg/dl) −0.114 1.318 (0.3) −0.205 3.702 (0.05) 
U8-OHdG (μg/g creatinine) — — 0.212 4.425 (0.04) 

Data are means ± SD. Mean values for HbA1c were calculated from the previous year.

This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan, and by grants from the Japan Diabetes Foundation, the Uehara Memorial Foundation, the Kanae Foundation for Life & Socio-Medical Science, and the Yamanouchi Foundation for Research on Metabolic Disorders.

We thank Dr. Masakazu Sakai of the Department of Biochemistry, Kumamoto University School of Medicine, Kumamoto, and Mr. Kenshi Ichinose, of our laboratory, for helpful advice and assistance.

A part of this study was presented in the oral presentation at the 61st annual meeting of American Diabetes Association, Philadelphia, 22–26 June 2001.

1.
Bierman EL: George Lyman Duff Memorial Lecture: atherogenesis in diabetes.
Arterioscler Thromb
12
:
647
–656,
1992
2.
Sanchez-Thorin JC: The epidemiology of diabetes mellitus and diabetic retinopathy.
Int Ophthalmol Clin
38
:
11
–18,
1998
3.
Brancati FL, Cusumano AM: Epidemiology and prevention of diabetic nephropathy.
Curr Opin Nephrol Hypertens
4
:
223
–229,
1995
4.
Group TG: Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia: the global lower extremity amputation study group.
Br J Surg
87
:
328
–337,
2000
5.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med
329
:
977
–986,
1993
6.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Diabetes Care
23(Suppl. 2)
:
B21
–B29,
2000
7.
Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M: Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.
Diabetes Res Clin Pract
48
:
201
–210,
2000
8.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
Diabetes Res Clin Pract
28
:
103
–117,
1995
9.
U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet
352
:
837
–853,
1998
10.
Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.
J Am Coll Cardiol
26
:
57
–65,
1995
11.
Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LE, Jensen-Urstad MT: Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM.
Diabetes
45
:
1253
–1258,
1996
12.
Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications.
Diabetes Care
19
:
257
–267,
1996
13.
Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
Nature
404
:
787
–790,
2000
14.
Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
Diabet Med
15
:
539
–553,
1998
15.
Kawamori R, Yamasaki Y, Matsushima H, Nishizawa H, Nao K, Hougaku H, Maeda H, Handa N, Matsumoto M, Kamada T: Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries.
Diabetes Care
15
:
1290
–1294,
1992
16.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories.
Circulation
97
:
1837
–1847,
1998
17.
Davis MD, Kern TS, Rand LI: Diabetic retinopathy. In
International Textbook of Diabetes Mellitus
. 2nd ed. Alberti KGMM, Zimmet P, DeFronzo RA, Eds. Chichester, UK, John Wiley,
1997
, p.
1413
–1446
18.
American Diabetes Association: Diabetic nephropathy.
Diabetes Care
23
:
S69
–S72,
2000
19.
Kaneko T, Tahara S, Matsuo M: Non-linear accumulation of 8-hydroxy-2′-deoxyguanosine, a marker of oxidized DNA damage, during aging.
Mutat Res
316
:
277
–285,
1996
20.
Ames BN: Endogenous oxidative DNA damage, aging, and cancer.
Free Radic Res
7
:
121
–128,
1989
21.
Erhola M, Toyokuni S, Okada K, Tanaka T, Hiai H, Ochi H, Uchida K, Osawa T, Nieminen MM, Alho H, Kellokumpu-Lehtinen P: Biomarker evidence of DNA oxidation in lung cancer patients: association of urinary 8-hydroxy-2′-deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment.
FEBS Lett
409
:
287
–291,
1997
22.
Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE: Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index.
Carcinogenesis
13
:
2241
–2247,
1992
23.
Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T: Oxidative damage to DNA in diabetes mellitus.
Lancet
347
:
444
–445,
1996
24.
Suzuki S, Hinokio Y, Komatu K, Ohtomo M, Onoda M, Hirai S, Hirai M, Hirai A, Chiba M, Kasuga S, Akai H, Toyota T: Oxidative damage to mitochondrial DNA and its relationship to diabetic complications.
Diabetes Res Clin Pract
45
:
161
–168,
1999
25.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study.
Circulation
96
:
1432
–1437,
1997
26.
Taniwaki H, Kawagishi T, Emoto M, Shoji T, Kanda H, Maekawa K, Nishizawa Y, Morii H: Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes: vessel wall properties in type 2 diabetes.
Diabetes Care
22
:
1851
–1857,
1999
27.
Beckman KB, Ames BN: The free radical theory of aging matures.
Physiol Rev
78
:
547
–581,
1998

Address correspondence and reprint requests to Takeshi Nishikawa, Department of Metabolic Medicine, Kumamoto University School of Medicine, 1-1-1 Honjo Kumamoto 860-8556, Japan. E-mail: [email protected].

Received for publication 24 May 2002 and accepted in revised form 21 January 2003.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.